

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/B/P1	го		Complete If Known		
				Application Number	10/823,396-Conf. #3661	
IN	<b>IFORMATION</b>	N DI	SCLOSURE	Filling Date	April 12, 2004	
S	TATEMENT!	BY A	APPLICANT	First Named Inventor	Marcus B. Jones	
				Art Unit	NA 1645	
	(Use as many sh	ieets as	necessary)	Examiner Name	Not Yet Assigned .	
Sheet	1	of	1	Attorney Docket Number	05986/100M724-US1	

	U.S. PATENT DOCUMENTS				
Examiner	Cite	Document Number	Publication Date	THE THE OF THE CONTROL OF	Pages, Columns, Lines, Where Relevant Passages or Relevant
Initials*	No.1	Number-Kind Code <sup>2</sup> ( # known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear

	FOREIGN PATENT DOCUMENTS					
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	Γ
Initials*	No.	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>6</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document	nt Where Relevant Passages or Relevant Figures Appear	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.usplo.gov">www.usplo.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English tanguage Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
SD	CA	Bourgogne, A.D., et al., "Bacillus anthracis harbors a functional orthologue of luxS, a gene essential for antoinducer-2 activity. Abstr. 101st General Meeting of the American Society for Microbiology, Orlando, FL., USA, 20-24 May 2001, page 127.	
SD	СВ	Jones, M.B., et al., "luxS-mediated quorum-sensing in Bacillus anthracis" Abstr. 103rd General Meeting of the American Society for Microbiology, Washington, D.C., USA, May 18-22, 2003, p. I-024.	
SD	CC	Jones, M.B., et al., "Detection of a luxS-signaling molecule in Bacillus anthracis" Infect. Immun. July 2003, Vol. 71, No. 7, pages 3914-3919, see Materials and Methods and Results	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	/C Dorri /	Date	02/05/0007
	/S. Devi/		03/06/2007
Signature		Considered	,,
		001.0.001.00	,

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

PTC/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE sound to a collection of information units a benefit of the collection of the collection

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

	Complete If Known				
Application Number	10/823,396				
Filing Date	April 12, 2004				
First Named Inventor	Marcus B. Jones				
Art Unit	1695				
Examiner Name	Not Yet Assigned				
Attorney Docket Number	05986/100M724-US1				

<u></u>	U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No.¹	Document Number Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

		FOREIG	GN PATENT (	DOCUMENTS		_
Examiner Initiats*	Cite No.	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>3</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
						├

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.usplo.gov">www.usplo.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. This is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
SD	CA	Adjei, et al. Pharmaceutical Research 1990; 7:565-569 and 63:135-144 (leuprolide acetate), "Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers."###	
SD	СВ	Bassler, Wright and Silverman. Mol. Microbiol. 1994; 13:273-286, "Multiple signaling systems controlling expression of luminescence in Vibrio harveyi: sequence and function of genes encoding a second sensory pathway."	
SD	CC	Benoist & Chambon, Nature 1981; 290:304-310l, "Sequence requirements of the SV40 early promotor region."	
SD	CD	Braquet, et al. J. Cardiovascular Pharmacology 1989;13 (sup5): 143-146 (endothelin-1) "Effect of endothelin-1 on blood pressure and bronchopulmonary system of the guinea pig."	
SD	CE	Brinster RL, et al., Nature 1982; 296:39-42, "Regulation of metallothionein-thymidine kinase fusion plasmids injected into mouse eggs."	
SD	CF	Chang TK et al., (1993) Cancer Res. 53:1043-1050, "Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes."	
SD	CG	Chen at al., Nature 2001; 415:545-549, Chen, X., S. Schauder, N. Potler, A. Dorsselaer, I. Pelczer, B. Bassler, and F. M. Hughson. 2001. "Structural identification of a bacterial quorum-sensing signal containing boron." Nature 415:545-549	
SD	СН	Cote et al., Proc. Natl. Acad. Sci. USA 1983;80:2026-2030, "Generation of Human Monoclonal Antibodies Reactive with Cellular Antigens,"	
SD	CI	Debs RJ, et al. J. Immunol. 1988; 140:3482-3488 (interferon- and tumor necrosis factor ) "Lung-specific delivery of cytokines induces sustained pulmonary and systemic immunomodulation in rats."	
SD	CJ	Greenberg, Hastings and Ulitzur. Arch. Microbiol. 1979; 120:87-91, "Not found on Medline, please provide reference."	
SD	CK_	Greener, et al., Strategies in Mol. Biol. 1995 7:32, "Not found on Medline, please provide reference."	
SD	CL	Guerot-Fleury, A., et al. Gene. 1995;167:335-336, "Antibiotic resistance cassettes for Bacillus	

Cupanina			
<b>Examiner</b>	/C Dend /	I Data	
	/S. Devi/	Date	03/06/2007
Signature	, ,	1	U3/U0/4UU/ I
Olginature		Considered	
		TOURIDIDOIGO	

Sut	Substitute for form 1449A/B/PTO			Complete If Known		
				Application Number	10/823,396	
11	NFORMATIC	ON DISC	LOSURE	Filing Date	April 12, 2004	
S	TATEMENT	<b>TBY AP</b>	PLICANT	First Named Inventor	Marcus B. Jones	
				Art Unit	1002 /645	
	(Use as many	sheets as nec	essary)	Examiner Name	Not Yet Assigned	
Sheet	2	of	3	Attorney Docket Number	05986/100M724-US1	

	1	reference."				
	СМ	Guerot-Fleury, A., et al. Gene. 1995;167:335-336, "Antibiotic resistance cassettes for Bacillus				
,SD	<u> </u>	subtilis."				
SD	CN	Hermes et al., Proc. Natl. Acad. Sci. USA 1990;87:696-700, "Searching Sequence Space by Definably Random Mutagenesis: Improving the Catalytic Potency of an Enzyme."				
	co	Hood et al., Immunology, Second Ed., 1984, Benjamin/Cummings: Menlo Park, California, p.				
SD		384, Book				
SD	CP	Hubbard, et al. (1989) Annals of Internal Medicine, Vol. III, pp. 206-212 (1-antitrypsin), Book chapter NOTE: Can be provided upon request.				
SD	CQ					
	CR	Bassler, Wright and Silverman. Mol. Microbiol. 1994; 13:273-286, "Multiple signaling systems				
SD		controlling expression of luminescence in Vibrio harveyi: sequence and function of genes				
		encoding a second sensory pathway."				
SD	cs	Jemigan JA, et al., Emer. Inf. Dis. 2001;7:933-933, "Bioterrorism-related inhalation anthrax:				
. עם	١٠٠	the first 10 cases reported in the United States."				
	CT	Kohler G & Milstein C, Nature 1975; 256:495-497, "Continuous cultures of fused cells				
SD	١٠'	secreting antibody of predefined specificity."				
SD	CU	Kozbor et al., Immunology Today 1983;4:72				
	CV	Loeffler DA et al. (1992) Cytom. 13: 169-174, "Analysis of distribution of tumor-and				
SD	• •	preneoplasia-infiltrating lymphocytes using simultaneous Hoechst 33342 labeling and				
עפ	1	immunophenotyping."				
	cw	Marshall, K. In: Modern Pharmaceutics Edited by G.S. Banker and C.T. Rhodes, Chapter 10,				
SD	~ ~ ~	1979 Book, NOTE: Can be provided upon request.				
	cx	Mock, M., and A. Fouet. Annu. Rev. Microbiol 2001;55:647-671Mock, M., and A. Fouet. 2001,				
SD	<u>\</u>	"Anthrax. Annu. Rev. Microbiol. 55:647-671"				
עפ	CY					
	101	Morrison et al., J. Bacteriol. 1984; 159:870, "Isolation of transformation-deficient Streptococcus pneumoniae mutants defective in control of competence, using insertion-duplication				
SD	1					
	cz	mutagenesis with the erythromycin resistance determinant of pAM beta 1."  Neuberger et al., Nature 1984;312:604-608, "Recombinant antibodies possessing novel				
SD	02	effector functions"				
	CA1	Nielsen PE et al., Science 1991, 254:1497, "Sequence-selective recognition of DNA by strand				
SD	J	displacement with thymine-substituted polyamide."				
	CB1	Provinciali M, et al., (1992) J. Immunol. Meth. 155:19-24, "Optimization of cytotoxic assay by				
SD	1001	target cell retention of the fluorescent dye carboxyfluorescein diacetate (CFDA) and				
	1	comparison with conventional 51CR release assay."				
	CC1	Ren, D. et al., Environ. Microbiol. 2001;3:731-736. "Inhibition of biofilm formation and				
- SD	100.	swarming of Escherichia coli by (5Z)-4-bromo-5-(bromomethylene)-3-butyl-2(5H)-furanone."				
	CD1	Ren, D. et al., Let. Appl. Microbil. 2002;34:293-299, "Inhibition of biofilm formation and				
SD	1	swarming of Bacillus subtilis by (5Z)-4-bromo-5-(bromomethylene)-3-butyl-2(5H)-furanone."				
	CE1	Rivoltini L et al., (1992) Can. Immunol. Immunother. 34: 241-251, "Phenotypic and functional				
SD		analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour				
		phenotype."				
SD	CF1	Scientific American 1980;242:74-94				
SD	CG1	Sirard, Mock and Foeut. J. Bacteriol. 1994;176:5188-92, "The three Bacillus anthracis toxin				
JU	1	genes are coordinately regulated by bicarbonate and temperature."				
	CH1	Takeda S et al., Nature 1985;314-452-454, "Construction of chimaeric processed				
SD	1	immunoglobulin genes containing mouse variable and human constant region sequences."				
	CI1	Villa-Komaroff L et al., proc. Natl. Acad. Sci, USA 1978;75:3727-3731, "A Bacterial Clone				
SD	5.1	Synthesizing Proinsulin."				
SD	CJ1	Vollenweider I et al., (1992) J. Immunol. Meth. 149:133-135, "Comparison of four DNA staining				
Examiner Signature		/S. Devi/ Date Considered 03/06/2007				
ogradie		Considered				

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2005. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Sound in a collection of information whose is continuous actifed the continuous.

Substitute for form 1449A/B/PTO				Complete If Known		
				Application Number	10/823,396	
IN	FORMATION	I DI	SCLOSURE	Filing Date	April 12, 2004	
STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	Marcus B. Jones	
				Art Unit	1632 1645	
				Examiner Name .	Not Yet Assigned	
Sheet	3	of	3	Attorney Docket Number	05986/100M724-US1	

		fluorescence dyes for measuring cell proliferation of lymphokine-activated killer (LAK) cells."	
SD	CK1	Wagner, et al., Proc. Natl. Acad. Sci. USA 1981; 78:1441-1445,	
SD	CL1	Yamamoto T, et al., Cell 1980;22:787-797, "Identification of a functional promoter in the long terminal repeat of Rous sarcoma virus."	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	' /a Dovri /	Date	20/20/202
Signature	/S. Devi/		03/06/2007
Signature		Considered	,

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.